Tempus AI valuation, Personalis acquisition, and governance concerns discussed
Summary
Speakers analyze Tempus AI's Q3 2026 financials, highlighting $411.5M in revenue and near break-even free cash flow. They discuss the $1.5B acquisition of Personalis, regulatory shifts in LDT pricing, and concerns over related-party transactions and capital allocation. The episode concludes with a valuation assessment classifying TEM as a speculative asset.
Key takeaways
- 1 Yeah. The waiting period for the uh Hart Scott Rodino Antitrust Improvements Act officially expired on October 2nd, 2026.
Unidentified speaker (speaker_1) · 8:18
Episode sections
- 0:00 – 3:04
Introduction to Tempus AI and Valuation Challenges
Speakers introduce Tempus AI (TEM) as a hybrid company at the intersection of genomic sequencing and AI, noting the difficulty in valuing such a complex business model compared to traditional labs or software companies.
- 3:04 – 6:36
Q3 2026 Financial Performance and Profitability
The discussion highlights Q3 2026 results showing $411.5M in net revenue (up 23.1% YoY), with Diagnostics generating $303.5M and Data/Applications generating $108.1M. Free cash flow broke even with a nominal outflow of $122,000.
- 6:36 – 7:41
Remaining Performance Obligations (RPO) and Contract Visibility
Speakers emphasize that RPO stands at $514M, indicating multi-year subscription contracts with pharma clients, which supports the sustainability of the recent profitability rather than suggesting an accounting anomaly.
- 7:41 – 8:32
Acquisition of Personalis (PSNL) and Regulatory Status
Tempus is acquiring Personalis for ~$1.5B ($16.25/share). HSR waiting period expired Oct 2, 2026, and UK CMA approved; final shareholder vote is Nov 30, 2026.
- 8:32 – 10:28
Strategic Value of MRD Testing and Product Integration
The acquisition adds Personalis' tumor-informed Minimal Residual Disease (MRD) test, allowing Tempus to offer end-to-end oncology services from initial diagnosis to long-term blood monitoring for cancer recurrence.
- 10:28 – 12:01
Institutional Shareholder Rotation
While Arc Investment Management trimmed positions in both TEM and PSNL, passive indexers like Vanguard are accumulating shares, signaling a transition from a volatile growth stock to a stabilized mid-cap healthcare index component.
- 12:01 – 15:24
The Data Moat and Multimodal Database
Tempus operates a dual-engine model: Diagnostics gathers data, while Data/Applications licenses it. The core asset is a 500-petabyte multimodal database linking genomic data with longitudinal electronic health records, creating a barrier to entry for AI/pharma competitors.
- 15:24 – 20:30
Synthetic Control Arms and Compute Cost Vulnerabilities
Tempus uses its data to create synthetic control arms for clinical trials, saving pharma companies time and money. However, the company relies on AWS/Google Cloud for compute, exposing it to pricing power risks from these tech giants.
- 20:30 – 22:16
SB Tempest JV and Google Cloud Debt Swap
Speakers discuss a Japanese joint venture, SB Tempest, capitalized with $95 million from both Tempus and SoftBank, noting Tempus immediately booked $95 million in revenue from it. They also detail a debt modification with Google Cloud involving a $250 million promissory note, where principal reduction was netted against cloud expenses, allegedly inflating adjusted EBITDA by $25.6 million.
- 22:16 – 24:48
Congressional Trading and Governance Concerns
The transcript highlights Representative Nancy Pelosi's options trades on Tempus (TEM), purchasing $20 strike calls in Jan 2025 and exercising them in Jan 2026 for significant upside. Speakers question the organic nature of revenue growth given related-party transactions and circular accounting maneuvers like the JV and debt swaps.
- 24:48 – 26:42
Regulatory Tailwinds and ADLT Pricing
Discussions cover the Trump administration's curtailment of FDA oversight on Laboratory Developed Tests (LDTs). Tempus strategically secured FDA approval for its xT CDX test to qualify for Advanced Diagnostic Laboratory Test (ADLT) status under CMS, increasing reimbursement from ~$2,900 to ~$4,500 per test without changing costs.
- 26:42 – 29:31
Macroeconomic Headwinds and Supply Chain Risks
Speakers analyze the impact of 15% Section 122 tariffs on imports, noting pharmaceuticals were exempted, protecting pharma R&D budgets and Tempus's data licensing clients. However, they highlight a critical vulnerability in Tempus's supply chain, specifically reliance on Illumina for flow cells and reagents amidst potential trade wars with China.
- 29:31 – 34:58
Capital Allocation and Dilution
Using a Bruce Greenwald analysis, speakers note low maintenance capex ($16.6M) but massive growth capex driven by cloud computing and AI R&D. They criticize the capital allocation strategy, citing the issuance of $1.84 billion in zero-percent convertible notes and heavy stock-based compensation, which dilutes shareholders.
- 34:58 – 41:20
Valuation and Investment Thesis
Tempus trades at 9.0x EV/Sales (FY26), cheaper than peer Natera (20.7x). The Rule of 40 score is 23 (25% growth + -2% FCF margin), justifying the discount. A sum-of-the-parts valuation suggests an accumulation target below $74.50. The stock is classified as a speculative venture-style asset incompatible with traditional value investing.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| Tempus AI, Inc.TEM | equity | mixed | No, because there are plenty of legacy lab companies that can sequence DNA perfectly well. But Tempest pairs that raw genomic data with longitudinal electronic health records. |
| AlphabetGOOGL | equity | neutral | Yes. Tempest executed a debt modification involving a $250 million promissory note held with Google. |
| ILLUMINA, INC.ILMN | equity | neutral | And they are heavily tethered to Illumina for that infrastructure. Trade wars and reciprocal export bans from China directly threaten the availability and the pricing of the raw materials Tempest needs just to keep the lights on in its physical labs. Trevor |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Total net revenue for Q3 2026 was $411.5 million, a 23.1% year-over-year increase.
Unidentified speaker (speaker_1) ·3:30
How to verify: Check Tempus AI's Q3 2026 Earnings Press Release or Form 10-Q filed with SEC EDGAR. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceDiagnostics segment generated $303.5 million and Data/Applications segment generated $108.1 million in Q3 2026.
Unidentified speaker (UNKNOWN) ·4:23
How to verify: Check Tempus AI's Q3 2026 Earnings Press Release or Form 10-Q filed with SEC EDGAR. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceFree cash flow for Q3 2026 was a nominal outflow of $122,000.
Unidentified speaker (speaker_0) ·5:42
How to verify: Check Tempus AI's Q3 2026 Earnings Press Release or Form 10-Q filed with SEC EDGAR for Cash Flow Statement. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceRemaining Performance Obligations (RPO) stood at $514 million.
Unidentified speaker (speaker_0) ·7:13
How to verify: Check Tempus AI's Q3 2026 Earnings Press Release or Form 10-Q filed with SEC EDGAR for Forward-Looking Metrics. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceThe acquisition of Personalis values the company at roughly $1.5 billion ($16.25 per share).
Unidentified speaker (speaker_0) ·7:52
How to verify: Check the definitive merger agreement or press release regarding the Tempus-Personalis transaction. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
The Hart-Scott-Rodino (HSR) waiting period expired on October 2, 2026.
Unidentified speaker (speaker_1) ·8:10
How to verify: Check SEC filings (Form 8-K or Proxy Statement) for the Tempus-Personalis merger regarding regulatory clearances. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceUK Competition and Markets Authority approved the Personalis acquisition.
Unidentified speaker (speaker_1) ·8:18
How to verify: Check UK CMA press releases or SEC filings for the Tempus-Personalis merger. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourcePersonalis shareholder vote is scheduled for November 30, 2026.
Unidentified speaker (speaker_1) ·8:25
How to verify: Check Personalis (PSNL) proxy materials or SEC filings for the meeting date. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceArc Investment Management sold roughly 1.6 million shares of Personalis in mid-October.
Unidentified speaker (speaker_1) ·10:52
How to verify: Check 13F filings for Arc Investment Management for the Q3 2026 reporting period. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourcePathos AI accounts for approximately $200 million of Tempus's total contract value (TCV).
Unidentified speaker (speaker_0) ·20:11
How to verify: Check Tempus AI's SEC filings (Form 10-K or 10-Q) for Related Party Transactions or Customer Concentration disclosures. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceSB Tempest was capitalized with roughly $95 million provided by Tempus and $95 million by SoftBank.
Unidentified speaker (speaker_0) ·20:40
How to verify: SEC EDGAR filings for Tempus AI (TEM) regarding joint venture disclosures and capital contributions; SoftBank investor relations materials. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceTempus immediately began recognizing $95 million in total contract value and revenue from the SB Tempest joint venture.
Unidentified speaker (UNKNOWN) ·20:51
How to verify: Tempus AI (TEM) quarterly earnings reports (10-Q) and 10-K filings, specifically the revenue recognition section and related party transactions. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceTempus executed a debt modification involving a $250 million promissory note with Google, netting principal reduction against cloud expenses.
Unidentified speaker (speaker_1) ·21:18
How to verify: Tempus AI (TEM) 10-K/10-Q filings detailing debt obligations, notes payable, and operating lease/cloud computing agreements. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceThe Google Cloud debt swap inflated adjusted EBITDA by approximately $25.6 million.
Unidentified speaker (UNKNOWN) ·21:36
How to verify: Tempus AI (TEM) reconciliation of GAAP to non-GAAP financial measures in earnings releases; forensic analysis of cloud expense vs. debt reduction. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Representative Nancy Pelosi purchased 50 TEM call options with a $20 strike price on January 14, 2025, and exercised them on January 16, 2026.
Unidentified speaker (speaker_1) ·22:26
How to verify: Congressional Financial Disclosure Reports (CFDR) filed by Rep. Pelosi via Capitol.gov or OpenSecrets.org; SEC Form 4 filings for insider transactions. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceTempus secured full FDA approval for its flagship xT CDX test.
Unidentified speaker (speaker_1) ·25:17
How to verify: FDA database of cleared or approved diagnostic tests; Tempus AI press releases regarding regulatory approvals for xT CDX. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Under the ADLT framework, Tempus can command roughly $4,500 per test, compared to ~$2,900 under LDT.
Unidentified speaker (speaker_0) ·26:04
How to verify: Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule or ADLT reimbursement rates; Tempus pricing disclosures or investor presentations. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
The administration imposed a 15% blanket tariff on global imports under Section 122 in February 2026, exempting pharmaceuticals.
Unidentified speaker (UNKNOWN) ·26:43
How to verify: Federal Register notices or official White House announcements regarding Section 122 tariffs and exemptions effective Feb 2026. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Tempus maintenance capex is approximately $16.6 million relative to over $1.2 billion in consolidated sales.
Unidentified speaker (speaker_1) ·29:46
How to verify: Tempus AI (TEM) cash flow statements and Bruce Greenwald-style capital allocation analysis found in financial news or analyst reports. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Tempus issued four $460 million zero-percent convertible notes to eliminate high-interest term loans.
Unidentified speaker (speaker_1) ·31:09
How to verify: SEC EDGAR filings for Tempus AI (TEM) detailing issuance of convertible notes, specifically the prospectus or 8-K filings announcing the debt offering. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Primary sourceTempus AI will be the most valuable healthcare company on Earth.
Unidentified speaker (speaker_1) ·41:07
How to verify: Monitor Tempus AI's market capitalization or enterprise value relative to other healthcare companies upon its potential public listing or through private market valuation updates; compare against public healthcare peers' market caps. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.
Do your own research
- Verify Q3 2026 10-Q filing for revenue breakdown and FCF details.
- Review SEC Schedule 14A for Personalis acquisition terms and shareholder vote date.
- Check HSR filing status and UK CMA approval documents for Personalis deal closure.
- Analyze Google Cloud debt modification terms and impact on adjusted EBITDA.
- Research Representative Nancy Pelosi's TEM options trades via Capitol Office financial disclosure reports.
- Confirm FDA ADLT status and CMS reimbursement rates for Tempus xT CDX test.
- Assess Illumina supply chain exposure and potential impact of Section 122 tariffs on reagents.
- Review convertible note indentures for dilution terms and zero-percent interest structures.
Full transcriptexpand
- 0:00
- Unidentified speaker (speaker_0): You know, um, when we normally think about getting a medical diagnosis, there's this there's a certain expectation of just binary precision, right?
- 0:09
- Unidentified speaker (UNKNOWN): Oh
- 0:09
- Unidentified speaker (speaker_1): yeah.
- 0:10
- Unidentified speaker (UNKNOWN): It
- 0:10
- Unidentified speaker (speaker_1): should be black and white.
- 0:11
- Unidentified speaker (speaker_0): Exactly.
- 0:11
- Unidentified speaker (UNKNOWN): It
- 0:11
- Unidentified speaker (speaker_0): feels almost like basic engineering. Like you break your arm, you go to the hospital, they take the x ray, and it shows that jagged white line on the bone.
- 0:20
- Unidentified speaker (speaker_1): Right. And the doctor just points to the film and says, Well, there it is.
- 0:22
- Unidentified speaker (speaker_0): Yeah. And it's I mean, it's deeply comforting to have that kind of visual certainty.
- 0:27
- Unidentified speaker (speaker_1): It really is. I mean, we inherently prefer biology to just be visible, right? Categorized and uh easily fixed.
- 0:34
- Unidentified speaker (UNKNOWN): You
- 0:35
- Unidentified speaker (speaker_1): see the problem, you apply the cast, and you move on. Aaron
- 0:37
- Unidentified speaker (UNKNOWN): Powell
- 0:37
- Unidentified speaker (speaker_0): But the reality is that the era of the simple X-ray diagnostic is completely obsolete, especially when you step into the world of precision oncology or genomic sequencing and obviously artificial intelligence. Oh,
- 0:50
- Unidentified speaker (speaker_1): absolutely. It's a completely different landscape now.
- 0:53
- Unidentified speaker (speaker_0): Yeah. And when I was pouring over the newly published 261106 Tempest AI Inc. report this morning, it just really struck me that we are looking at the absolute definition of diagnostic muddy waters here. Aaron
- 1:05
- Unidentified speaker (UNKNOWN): Powell
- 1:05
- Unidentified speaker (speaker_1): Muddy's probably the best word for it.
- 1:07
- Unidentified speaker (speaker_0): Right. Because we're trying to place a hard financial valuation on a company that's operating at this incredibly murky intersection of massive biological data sets and frontier AI.
- 1:21
- Unidentified speaker (UNKNOWN): Aaron Powell
- 1:21
- Unidentified speaker (speaker_1): And uh that intersection is arguably the most complex sector in the modern public markets right now. Aaron
- 1:26
- Unidentified speaker (UNKNOWN): Powell
- 1:26
- Unidentified speaker (speaker_0): Without a doubt.
- 1:28
- Unidentified speaker (speaker_1): Because y you're no longer just valuing a laboratory that runs standard blood tests, nor are you simply valuing, you know, a Silicon Valley software company writing code. Aaron
- 1:37
- Unidentified speaker (UNKNOWN): Powell
- 1:37
- Unidentified speaker (speaker_0): Yeah, it's not just SaaS. Aaron
- 1:38
- Unidentified speaker (UNKNOWN): Powell
- 1:38
- Unidentified speaker (speaker_1): Exactly. You are attempting to price an entirely new hybrid business model. Aaron
- 1:42
- Unidentified speaker (UNKNOWN): Powell
- 1:42
- Unidentified speaker (speaker_0): Which is exactly what we're doing for you today. So welcome to the deep dive.
- 1:46
- Unidentified speaker (speaker_1): Glad to be here.
- 1:47
- Unidentified speaker (speaker_0): If you are joining us, you are likely looking to understand where healthcare technology is actually heading, and more importantly, how to actually invest in it. Aaron
- 1:56
- Unidentified speaker (UNKNOWN): Powell
- 1:57
- Unidentified speaker (speaker_1): Right. The investment angle is key.
- 1:58
- Unidentified speaker (UNKNOWN): Aaron Powell
- 1:58
- Unidentified speaker (speaker_0): So our mission today is to conduct a rigorous comprehensive investment. analysis of Tempest AI Inc., which trades under the ticker TEM.
- 2:08
- Unidentified speaker (speaker_0): Yep. And we are going to use that 261106 Tempest report as our primary anchor, but um we're also pulling in their absolute latest SEC filings and current market data just to give you the complete picture. Aaron
- 2:20
- Unidentified speaker (UNKNOWN): Powell
- 2:20
- Unidentified speaker (speaker_1): Because you really need all those pieces to see what's actually happening. Aaron
- 2:23
- Unidentified speaker (UNKNOWN): Powell
- 2:23
- Unidentified speaker (speaker_0): Exactly. I mean we're talking about a company that's fortified by this multiple multipetabyte data moat. They're pioneering agentic AI and drug discovery. But, and this is a big butt, they are also trailing some severe forensic accounting red flags.
- 2:37
- Unidentified speaker (speaker_1): Yeah, some very interesting filings there. Aaron
- 2:39
- Unidentified speaker (UNKNOWN): Powell
- 2:39
- Unidentified speaker (speaker_0): Plus a history of massive structural shareholder dilution.
- 2:43
- Unidentified speaker (speaker_1): Right.
- 2:43
- Unidentified speaker (speaker_0): And all of this is playing out amid the macroeconomic chaos of the second year of Trump 2.0. Aaron
- 2:48
- Unidentified speaker (UNKNOWN): Powell,
- 2:48
- Unidentified speaker (speaker_1): which just adds a whole other layer of complexity. to the supply chain and pricing.
- 2:53
- Unidentified speaker (speaker_0): It really does. Okay, let's unpack this. Before we can even begin to model out where Tempest is going in the next decade, we have to establish a rock solid baseline of their financial health today. Aaron
- 3:04
- Unidentified speaker (UNKNOWN): Powell
- 3:04
- Unidentified speaker (speaker_0): Right
- 3:04
- Unidentified speaker (speaker_1): you have to know where they stand right now.
- 3:06
- Unidentified speaker (speaker_0): Yeah. Specifically looking at the updates since the latest earnings report.
- 3:10
- Unidentified speaker (UNKNOWN): Aaron Trevor Powell Burrus
- 3:10
- Unidentified speaker (speaker_1): And uh the best place to ground that baseline is the Q3 2026 earnings print.
- 3:15
- Unidentified speaker (speaker_0): The one that just came out, right. Trevor
- 3:17
- Unidentified speaker (UNKNOWN): Burrus
- 3:17
- Unidentified speaker (speaker_1): Exactly. Released on November 2nd, 2026. And for anyone who has been tracking Tempest since its IPO, I mean, these numbers represent a dramatic structural maturation of the business. Aaron
- 3:28
- Unidentified speaker (UNKNOWN): Powell
- 3:28
- Unidentified speaker (speaker_0): How dramatic are we talking?
- 3:30
- Unidentified speaker (speaker_1): Well, total net revenue for the third quarter hit $411.5 million. Aaron
- 3:34
- Unidentified speaker (UNKNOWN): Powell?
- 3:34
- Unidentified speaker (speaker_0): $411 million.
- 3:36
- Unidentified speaker (UNKNOWN): Yeah.
- 3:36
- Unidentified speaker (speaker_0): Wow. Aaron
- 3:36
- Unidentified speaker (UNKNOWN): Powell That
- 3:37
- Unidentified speaker (speaker_1): is a $23.1%.
- 3:39
- Unidentified speaker (speaker_1): year-over-year increase. Aaron
- 3:40
- Unidentified speaker (UNKNOWN): Powell
- 3:41
- Unidentified speaker (speaker_0): That's substantial for a company this size.
- 3:43
- Unidentified speaker (speaker_1): It is. I mean, to put that $411 million in perspective, Tempest is essentially generating more top-line revenue in a single quarter than many of their legacy publicly traded biotech peers generate in two full years.
- 3:57
- Unidentified speaker (speaker_0): Let's let's pause on that number for a second, though, because top-line revenue and diagnostics, it can sometimes be a vanity metric, right? Trevor
- 4:03
- Unidentified speaker (UNKNOWN): Burrus, Jr. Oh,
- 4:03
- Unidentified speaker (speaker_1): completely.
- 4:05
- Unidentified speaker (UNKNOWN): Trevor Burrus, Jr.:
- 4:06
- Unidentified speaker (speaker_0): Like if they are just running millions of low-margin standard blood tests just to pump up that $411 million, that doesn't necessarily make them a great technology investment. Aaron
- 4:16
- Unidentified speaker (UNKNOWN): Powell
- 4:16
- Unidentified speaker (speaker_1): Right. It just makes them a busy lab. Aaron
- 4:17
- Unidentified speaker (UNKNOWN): Powell
- 4:18
- Unidentified speaker (speaker_0): Exactly. So where is that revenue actually coming from? Aaron
- 4:21
- Unidentified speaker (UNKNOWN): Powell
- 4:21
- Unidentified speaker (speaker_1): That is the critical distinction here.
- 4:23
- Unidentified speaker (UNKNOWN): So
- 4:23
- Unidentified speaker (speaker_1): the physical diagnostics segment, the actual running of the physical tests, generated $303.5 million of that total.
- 4:31
- Unidentified speaker (speaker_0): Okay. So that's the foundational business.
- 4:33
- Unidentified speaker (speaker_1): Yes. But the standout segment, the one driving the core investment thesis, is their data and applications division. Aaron
- 4:40
- Unidentified speaker (UNKNOWN): Powell
- 4:40
- Unidentified speaker (speaker_0): Right, the AI side. Aaron
- 4:41
- Unidentified speaker (UNKNOWN): Ross Powell
- 4:42
- Unidentified speaker (speaker_1): Exactly. That segment delivered $108.1 million. dollars.
- 4:45
- Unidentified speaker (speaker_0): Over a hundred million just on data.
- 4:48
- Unidentified speaker (speaker_1): Yeah. And this is software style high market. margin revenue where they are licensing their proprietary biological data directly to pharmaceutical companies. Aaron
- 4:56
- Unidentified speaker (UNKNOWN): Powell
- 4:56
- Unidentified speaker (speaker_0): Which is where the real value is. And for anyone holding TEM in their portfolio right now, the absolute most critical nugget in this Q3 print isn't even the revenue beat, is it?
- 5:07
- Unidentified speaker (speaker_1): No, it's the profitability inflection.
- 5:09
- Unidentified speaker (speaker_0): Right. Because for years the major institutional knock on tempest was just this relentless cash burn.
- 5:15
- Unidentified speaker (speaker_1): They were viewed as a total cash incinerator, just burning through capital.
- 5:19
- Unidentified speaker (speaker_0): Yeah.
- 5:20
- Unidentified speaker (UNKNOWN): But
- 5:20
- Unidentified speaker (speaker_0): in Q3, the gap net loss narrowed from an eighty million dollar crater in the prior year quarter down to just 14.9 million. Aaron
- 5:29
- Unidentified speaker (UNKNOWN): Powell,
- 5:29
- Unidentified speaker (speaker_1): which is a massive improvement on paper.
- 5:32
- Unidentified speaker (speaker_0): But if we strip away the accounting noise, you know, and look at the actual cash leaving the bank account, free cash flow affected. effectively broke even.
- 5:39
- Unidentified speaker (UNKNOWN): Yeah,
- 5:40
- Unidentified speaker (speaker_1): that was the most surprising part of the report.
- 5:42
- Unidentified speaker (speaker_0): They recorded a nominal cash outflow of just $122,000 for the entire three-month period.
- 5:48
- Unidentified speaker (speaker_1): Essentially a rounding error for a company this size. Aaron
- 5:51
- Unidentified speaker (UNKNOWN): Powell
- 5:51
- Unidentified speaker (speaker_0): Right. And operating margins improved by a massive 4.4 percentage points.
- 5:55
- Unidentified speaker (speaker_1): It's a very sharp pivot.
- 5:57
- Unidentified speaker (speaker_0): It really is. I mean, it feels like watching a massive, heavy cargo ship finally turn off its cash burning engines and just effortlessly glide forward on its own momentum.
- 6:07
- Unidentified speaker (speaker_1): That's a good way to picture it.
- 6:08
- Unidentified speaker (speaker_0): But I do have to play devil's advocate here for a second.
- 6:11
- Unidentified speaker (speaker_1): Sure.
- 6:11
- Unidentified speaker (speaker_0): When a historic cash burner suddenly posts a negative $122,000 free cash flow quarter, is that break even point a true sustainable turning point for the business?
- 6:23
- Unidentified speaker (UNKNOWN): Or
- 6:23
- Unidentified speaker (speaker_1): is it just an illusion? Aaron
- 6:24
- Unidentified speaker (UNKNOWN): Powell
- 6:24
- Unidentified speaker (speaker_0): Yeah. Like are we just looking at a clever work? working capital accounting anomaly for one quarter just to appease Wall Street? Aaron
- 6:31
- Unidentified speaker (UNKNOWN): Powell
- 6:31
- Unidentified speaker (speaker_1): It's a fair question. But what's fascinating here is the forward visibility embedded in their contracts. Aaron
- 6:36
- Unidentified speaker (UNKNOWN): Powell
- 6:36
- Unidentified speaker (speaker_0): Okay. What do you mean? Aaron
- 6:37
- Unidentified speaker (UNKNOWN): Powell
- 6:37
- Unidentified speaker (speaker_1): Well, if this were just an accounting trick, say uh aggressively pulling forward receivables or you know delaying vendor payments until Q4, you wouldn't see the corresponding strength in their RPO. Aaron
- 6:47
- Unidentified speaker (UNKNOWN): Powell
- 6:47
- Unidentified speaker (speaker_0): The remaining performance obligations?
- 6:49
- Unidentified speaker (speaker_1): Exactly.
- 6:50
- Unidentified speaker (speaker_0): And just to clarify for everyone listening, remaining performance obligations represent the contracted revenue that biopharma clients are legally locked in to pay Tempest, but that Tempest just hasn't recognized on the income statement yet because the service is still ongoing. Aaron
- 7:05
- Unidentified speaker (UNKNOWN): Powell
- 7:05
- Unidentified speaker (speaker_1): Precisely. It's guaranteed future revenue, essentially. And that RPO currently stands at $514 million. Aaron
- 7:12
- Unidentified speaker (UNKNOWN): Powell
- 7:13
- Unidentified speaker (speaker_0): Over half a billion dollars of
- 7:14
- Unidentified speaker (UNKNOWN): the remote.
- 7:14
- Unidentified speaker (speaker_0): in backlog.
- 7:15
- Unidentified speaker (speaker_1): Yeah. That half billion dollar backlog proves that this Q3 revenue generation isn't a one-off spike.
- 7:21
- Unidentified speaker (speaker_0): Right. It's not a fluke.
- 7:22
- Unidentified speaker (speaker_1): No. It represents deep multi-year contract visibility. I mean, the pharmaceutical giants aren't just buying one single data set.
- 7:29
- Unidentified speaker (UNKNOWN): They
- 7:29
- Unidentified speaker (speaker_1): are signing multi-year subscription agreements to constantly query the Tempest platform.
- 7:34
- Unidentified speaker (speaker_0): Wow. And alongside these organic internal numbers, we have massive inorganic movement that we really need to factor into the thesis.
- 7:41
- Unidentified speaker (speaker_2): The acquisition.
- 7:42
- Unidentified speaker (speaker_0): Yes. The pending acquisition of Personalis, ticker PSNL. Tempest is absorbing them in a deal that values Personalis at roughly $1.5 billion. Aaron
- 7:51
- Unidentified speaker (UNKNOWN): Powell,
- 7:51
- Unidentified speaker (speaker_1): which is a huge move.
- 7:52
- Unidentified speaker (speaker_0): It is. It shakes out to $16.25 per share.
- 7:57
- Unidentified speaker (UNKNOWN): And
- 7:57
- Unidentified speaker (speaker_1): this is a major consolidation play in the sector. Aaron
- 8:00
- Unidentified speaker (UNKNOWN): Powell,
- 8:00
- Unidentified speaker (speaker_0): what about the regulatory side? That's usually the big biggest hurdle in these billion-dollar healthcare mergers, right?
- 8:05
- Unidentified speaker (speaker_1): Usually, yes. But that risk is effectively cleared at this point. Aaron
- 8:09
- Unidentified speaker (UNKNOWN): Powell
- 8:09
- Unidentified speaker (speaker_0): Really? Already.
- 8:10
- Unidentified speaker (speaker_1): Yeah. The waiting period for the uh Hart Scott Rodino Antitrust Improvements Act officially expired on October 2nd, 2026.
- 8:17
- Unidentified speaker (speaker_0): Oh wow.
- 8:18
- Unidentified speaker (speaker_1): And they also secured the green light from the UK Competition and Markets Authority.
- 8:22
- Unidentified speaker (UNKNOWN): Trevor Burrus
- 8:22
- Unidentified speaker (speaker_0): So the regulatory red tape is basically gone.
- 8:25
- Unidentified speaker (speaker_1): Yep.
- 8:25
- Unidentified speaker (UNKNOWN): The
- 8:25
- Unidentified speaker (speaker_1): final administrative hurdle is simply the personalis special shareholder vote, which is scheduled for November 30th, 2026. Aaron
- 8:32
- Unidentified speaker (UNKNOWN): Powell
- 8:32
- Unidentified speaker (speaker_0): So let's talk about why Tempest is actually spending $1.5 billion on this. I mean, from a strategic standpoint, acquiring personalis brings the next personal MRD test directly into Tempest's arsenal. Aaron Powell
- 8:43
- Unidentified speaker (speaker_1): Yes. The MRD test is the crown jewel of that deal.
- 8:46
- Unidentified speaker (UNKNOWN): Aaron Powell Ross
- 8:46
- Unidentified speaker (speaker_0): And MRD stands for minimal residual disease.
- 8:49
- Unidentified speaker (speaker_1): Right.
- 8:50
- Unidentified speaker (speaker_0): So if we are looking at the actual mechanics of this, how does this tumor-informed test actually change Tempest's product lineup?
- 8:58
- Unidentified speaker (UNKNOWN): Aaron Powell
- 8:58
- Unidentified speaker (speaker_1): Think of treating cancer like weeding a massive garden, right? Surgeon goes in and removes the visible tumor. They pull the main weed. Trevor
- 9:05
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 9:05
- Unidentified speaker (speaker_0): Right, the obvious part.
- 9:07
- Unidentified speaker (speaker_1): But the terrifying part of oncology is knowing whether microscopic, completely invisible seeds have been left behind in the soil. Aaron
- 9:14
- Unidentified speaker (UNKNOWN): Powell
- 9:14
- Unidentified speaker (speaker_0): Because you can't see them on a normal scan. Aaron
- 9:16
- Unidentified speaker (UNKNOWN): Powell
- 9:16
- Unidentified speaker (speaker_1): Exactly. Traditional scans won't see them until they grow into new weeds months or even years later.
- 9:21
- Unidentified speaker (UNKNOWN): Aaron Powell So
- 9:21
- Unidentified speaker (speaker_0): how does the next personal test fix that? Aaron
- 9:24
- Unidentified speaker (UNKNOWN): Powell
- 9:24
- Unidentified speaker (speaker_1): Well, the test is what we call tumor-informed, meaning they take the actual DNA of the patient's specific surgically removed tumor
- 9:32
- Unidentified speaker (UNKNOWN): and
- 9:33
- Unidentified speaker (speaker_1): they identify its unique genetic fingerprint.
- 9:35
- Unidentified speaker (speaker_0): Okay.
- 9:36
- Unidentified speaker (speaker_1): And then they continually test the patient's blood over
- 9:38
- Unidentified speaker (UNKNOWN): the same.
- 9:39
- Unidentified speaker (speaker_1): time
- 9:39
- Unidentified speaker (UNKNOWN): to
- 9:40
- Unidentified speaker (speaker_1): see if even a single molecule of that specific DNA is floating around.
- 9:44
- Unidentified speaker (speaker_0): Wow.
- 9:44
- Unidentified speaker (speaker_1): Yeah.
- 9:45
- Unidentified speaker (speaker_0): So it's looking for the exact signature of that one patient's cancer. Aaron
- 9:48
- Unidentified speaker (UNKNOWN): Powell
- 9:49
- Unidentified speaker (speaker_1): Precisely. It is the ultimate early warning system. Aaron
- 9:52
- Unidentified speaker (UNKNOWN): Powell
- 9:52
- Unidentified speaker (speaker_0): That is incredible.
- 9:54
- Unidentified speaker (speaker_1): And by bringing this in-house, Tempest can now offer For oncologists a complete end-to-end service. Aaron
- 9:59
- Unidentified speaker (UNKNOWN): Powell
- 9:59
- Unidentified speaker (speaker_0): Right, because before they just did the initial diagnosis.
- 10:02
- Unidentified speaker (speaker_1): Exactly. Now they diagnose the initial tumor, they recommend the targeted drug, and then they continuously monitor the blood for years to ensure the cancer hasn't returned.
- 10:11
- Unidentified speaker (speaker_0): It is a massive upgrade to their diagnostic funnel.
- 10:14
- Unidentified speaker (speaker_1): Massive.
- 10:15
- Unidentified speaker (speaker_0): And the market clearly recognized the synergy there. I mean, on the heels of the Q3 earnings and that HSR clearance, Tempest shares rallied past seventy-seven $77 dollars intraday.
- 10:25
- Unidentified speaker (speaker_1): It was a very strong market reaction.
- 10:28
- Unidentified speaker (speaker_0): But, and this is where you have to look deeper, if you dig into the 13F filings and look at the institutional flows over the last 90 days, there is a very interesting rotation happening beneath the surface. Aaron
- 10:38
- Unidentified speaker (UNKNOWN): Powell
- 10:39
- Unidentified speaker (speaker_1): Yeah, the uh institutional musical chairs, so to speak.
- 10:42
- Unidentified speaker (speaker_0): Right. Arc Investment Management, who we all know was very prominent, very vocal early backer of both Tempest and Personnalis, Personalis. they've actually been trimming their positions.
- 10:52
- Unidentified speaker (speaker_1): Right.
- 10:52
- Unidentified speaker (speaker_0): They sold roughly 1.6 million shares of Personnalis in mid-October and continued trimming their Tempest position into that post-earning strength. Aaron
- 11:01
- Unidentified speaker (UNKNOWN): Powell
- 11:01
- Unidentified speaker (speaker_1): And you know, seeing a high-profile growth fund like ARC take profits or reallocate can sometimes spook retail investors. Trevor
- 11:08
- Unidentified speaker (UNKNOWN): Burrus
- 11:08
- Unidentified speaker (speaker_0): Oh, for sure. People see Kathy Wood selling and they panic. Trevor
- 11:11
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 11:11
- Unidentified speaker (speaker_1): Exactly. However, you have to look at who is taking the other side of the that trade.
- 11:15
- Unidentified speaker (speaker_0): Right. Who's buying what ARC is selling? Aaron Powell
- 11:17
- Unidentified speaker (speaker_1): The massive, passive indexers are stepping in to absorb that liquidity. Like
- 11:21
- Unidentified speaker (speaker_0): Vanguard?
- 11:22
- Unidentified speaker (speaker_1): Exactly. Vanguard and other institutional behemoths are aggressively accumulating the stock right now.
- 11:27
- Unidentified speaker (speaker_0): So it's moving from active growth funds to passive index funds.
- 11:31
- Unidentified speaker (speaker_1): Yes. And this is actually a very healthy sign of corporate maturation. Aaron
- 11:35
- Unidentified speaker (UNKNOWN): Powell
- 11:35
- Unidentified speaker (speaker_0): Because it stabilizes the base.
- 11:37
- Unidentified speaker (speaker_1): Exactly. Tempest's Tempest trade. is transitioning from being a highly volatile venture-backed story stock into a solidified mid-cap healthcare index component.
- 11:46
- Unidentified speaker (speaker_0): Okay, so we have a stabilizing shareholder base, we have free cash flow practically at break-even, and we have a major strategic acquisition closing.
- 11:56
- Unidentified speaker (speaker_1): All very positive signs. Trevor
- 11:57
- Unidentified speaker (UNKNOWN): Burrus
- 11:57
- Unidentified speaker (speaker_0): But we need to answer the foundational question for any long-term investor here.
- 12:01
- Unidentified speaker (UNKNOWN): Right.
- 12:01
- Unidentified speaker (speaker_0): Why are these biofinance? biopharma companies pouring hundreds of millions of dollars into Tempest in the first place? Aaron
- 12:06
- Unidentified speaker (UNKNOWN): Powell
- 12:06
- Unidentified speaker (speaker_1): What's the actual value proposition? Aaron
- 12:08
- Unidentified speaker (UNKNOWN): Ross Powell
- 12:08
- Unidentified speaker (speaker_0): Exactly. To understand the underlying economics, we have to look at the core engine of the company. Aaron
- 12:13
- Unidentified speaker (UNKNOWN): Powell
- 12:14
- Unidentified speaker (speaker_1): Because it's not just a traditional lab. Aaron
- 12:16
- Unidentified speaker (UNKNOWN): Powell
- 12:16
- Unidentified speaker (speaker_0): No. Tempus operates on a dual engine architecture that has created what the analysts are calling an insurmountable data moat. Aaron
- 12:24
- Unidentified speaker (UNKNOWN): Powell
- 12:24
- Unidentified speaker (speaker_1): And it really helps to visualize the business model as as a massive, highly sophisticated funnel.
- 12:30
- Unidentified speaker (speaker_0): Okay, walk us through the funnel.
- 12:32
- Unidentified speaker (speaker_1): So at the top of the funnel is the physical diagnostic segment. Aaron
- 12:36
- Unidentified speaker (UNKNOWN): Powell
- 12:36
- Unidentified speaker (speaker_0): The physical labs.
- 12:37
- Unidentified speaker (speaker_1): Right. These are the physical laboratories across the country, processing the tissue biopsies and the blood samples.
- 12:43
- Unidentified speaker (speaker_0): Just normal lab work.
- 12:44
- Unidentified speaker (speaker_1): Exactly. They sequence the DNA to help the doctor treat the patient today. Aaron
- 12:48
- Unidentified speaker (UNKNOWN): Powell
- 12:48
- Unidentified speaker (speaker_0): But that's just the top of the funnel.
- 12:50
- Unidentified speaker (speaker_1): Exactly. That is only the beginning of the value chain. That clinical and molecular data is then anonymized, stripped of personal identifiers, harmonized into a standard format, and transferred down the funnel into the data and application segment.
- 13:04
- Unidentified speaker (speaker_0): And the scale of this database is, frankly, hard to wrap your head around. I mean, the report cites a 500-petabyte multimodal database. Aaron
- 13:13
- Unidentified speaker (UNKNOWN): Powell
- 13:13
- Unidentified speaker (speaker_1): It is an astronomical. amount of biological data. Trevor
- 13:16
- Unidentified speaker (UNKNOWN): Burrus
- 13:16
- Unidentified speaker (speaker_0): It really is. But I want to focus on that word, multimodal. Why does multimodal matter so much? Why is this 500-petabyte moat so much more valuable than, say, a competitor who just sequences a lot of DNA? Aaron
- 13:31
- Unidentified speaker (UNKNOWN): Powell
- 13:31
- Unidentified speaker (speaker_1): Because raw DNA data in a vacuum is virtually useless to a pharmaceutical researcher. Aaron
- 13:35
- Unidentified speaker (UNKNOWN): Powell
- 13:36
- Unidentified speaker (speaker_0): Really? Yeah. Just knowing the mutation isn't enough. Aaron
- 13:38
- Unidentified speaker (UNKNOWN): Powell
- 13:38
- Unidentified speaker (speaker_1): No, because there are plenty of legacy lab companies that can sequence DNA perfectly well. But Tempest pairs that raw genomic data with longitudinal electronic health records.
- 13:48
- Unidentified speaker (speaker_0): Oh, so they link the DNA to the patient's actual medical history.
- 13:52
- Unidentified speaker (speaker_1): Exactly.
- 13:53
- Unidentified speaker (UNKNOWN): Yeah,
- 13:54
- Unidentified speaker (speaker_1): they are connecting the molecular profile of a specific tumor with the actual real-world clinical outcomes of that specific patient over the course of years.
- 14:02
- Unidentified speaker (speaker_0): Wow.
- 14:03
- Unidentified speaker (speaker_1): So they know what the mutation was, what drug the doctor prescribed, how the tumor reacted to that drug, and ultimately how long the patient survived.
- 14:11
- Unidentified speaker (speaker_0): So it's the full story, not just a snapshot.
- 14:13
- Unidentified speaker (speaker_1): That connected multimodal history is the holy grail for drug developers.
- 14:18
- Unidentified speaker (speaker_0): Which completely explains why the tech giants and pharma companies are just lining up at Tempest's door. Trevor
- 14:23
- Unidentified speaker (UNKNOWN): Burrus
- 14:24
- Unidentified speaker (speaker_1): They have to. They don't have a choice.
- 14:26
- Unidentified speaker (speaker_0): Right.
- 14:26
- Unidentified speaker (UNKNOWN): I
- 14:27
- Unidentified speaker (speaker_0): mean we are watching frontier AI laps like OpenAI and Anthropic trying to build biological foundation models and pharma giants like Pfizer and GSK trying to design next generation targeted therapies. Aaron
- 14:37
- Unidentified speaker (UNKNOWN): Ross
- 14:37
- Unidentified speaker (speaker_0): Powell
- 14:37
- Unidentified speaker (speaker_1): And they are all running into the exact same wall.
- 14:40
- Unidentified speaker (speaker_0): The data bottleneck.
- 14:41
- Unidentified speaker (speaker_1): Exactly. They all share the exact same bottleneck. You cannot train biological AI models on data scraped from Wikipedia or Reddit.
- 14:51
- Unidentified speaker (speaker_0): Right. ChatGPT can learn English from Reddit, but it can't learn oncology.
- 14:55
- Unidentified speaker (speaker_1): Precisely. You need HIPAA compliant, clinically validated, multi-omic data sets.
- 15:00
- Unidentified speaker (speaker_0): And Tempus is sitting there perfectly positioned as the undisputed toll collector for the only data that matters.
- 15:06
- Unidentified speaker (speaker_1): They essentially control the raw material that the entire AI healthcare ecosystem demands right now.
- 15:12
- Unidentified speaker (UNKNOWN): If
- 15:12
- Unidentified speaker (speaker_0): you want to play, you have to pay the tool.
- 15:15
- Unidentified speaker (speaker_1): Yes.
- 15:15
- Unidentified speaker (UNKNOWN): If you
- 15:15
- Unidentified speaker (speaker_1): want to train an AI to predict cancer mutations, you must pay Tempest for the training data.
- 15:20
- Unidentified speaker (UNKNOWN): Aaron Powell But
- 15:21
- Unidentified speaker (speaker_0): here's where it gets really interesting.
- 15:23
- Unidentified speaker (UNKNOWN): Yeah.
- 15:24
- Unidentified speaker (speaker_0): Tempest isn't just sitting back and passively licensing this data like some static library.
- 15:29
- Unidentified speaker (speaker_1): No, they're much more active than that.
- 15:31
- Unidentified speaker (speaker_0): They are actively deploying agentic AI tools through their lens platform to help these pharma partners completely bypass traditional. incredibly expensive clinical trial hurdles.
- 15:41
- Unidentified speaker (speaker_1): The synthetic control arms.
- 15:43
- Unidentified speaker (speaker_0): Yes. One of the primary use cases highlighted in the report is designing these synthetic control arms.
- 15:48
- Unidentified speaker (speaker_1): Which is just a revolutionary application of the data. Aaron
- 15:50
- Unidentified speaker (UNKNOWN): Powell
- 15:50
- Unidentified speaker (speaker_0): So for people who don't know the clinical trial process, how does a synthetic control arm actually work?
- 15:56
- Unidentified speaker (speaker_1): Well, historically, if a pharmaceutical company wanted to test a new cancer drug, they had to recruit hundreds of patients.
- 16:02
- Unidentified speaker (speaker_0): Which takes forever.
- 16:04
- Unidentified speaker (speaker_1): It does. And half of those patients get the experimental, potentially life-saving drug.
- 16:09
- Unidentified speaker (speaker_0): And the other half?
- 16:10
- Unidentified speaker (UNKNOWN): The
- 16:10
- Unidentified speaker (speaker_1): other half. The control arm, they get the standard of care, which is essentially a placebo or just the older, less effective drug.
- 16:16
- Unidentified speaker (speaker_0): That's awful.
- 16:17
- Unidentified speaker (speaker_1): It takes years to recruit these patients. It costs tens of millions of dollars. And ethically, it is profoundly difficult to tell a terminally ill patient they are in the control group.
- 16:27
- Unidentified speaker (speaker_0): I can't even imagine.
- 16:28
- Unidentified speaker (UNKNOWN): But
- 16:28
- Unidentified speaker (speaker_0): with Tempest's 500 petabyte database, you don't need a physical control arm anymore. Trevor
- 16:34
- Unidentified speaker (UNKNOWN): Burrus, Jr.:
- 16:34
- Unidentified speaker (speaker_1): Exactly the point. Because Tempest has the historical records of millions of patients, the AI can instantly generate a synthetic control arm.
- 16:41
- Unidentified speaker (UNKNOWN): Aaron Powell
- 16:42
- Unidentified speaker (speaker_0): So it just finds matches in the database.
- 16:44
- Unidentified speaker (speaker_1): Yes. It finds thousands of historical patients in the database who perfectly match the genetic and demographic profile of the actual people in your trial.
- 16:52
- Unidentified speaker (speaker_0): Wow.
- 16:53
- Unidentified speaker (UNKNOWN): And
- 16:53
- Unidentified speaker (speaker_1): it shows you exactly how they responded to the standard of care in the past. Aaron
- 16:57
- Unidentified speaker (UNKNOWN): Ross Powell So
- 16:57
- Unidentified speaker (speaker_0): you save years of trial time. Aaron Powell
- 16:59
- Unidentified speaker (speaker_1): Years of time and billions of dollars in RD costs. Trevor
- 17:03
- Unidentified speaker (UNKNOWN): Burrus
- 17:03
- Unidentified speaker (speaker_0): So if we think of precision oncology as a modern-day gold rush, Tempest isn't just out there in the mud mining the gold through their diagnostic labs.
- 17:11
- Unidentified speaker (speaker_1): They own the map. Trevor
- 17:12
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 17:12
- Unidentified speaker (speaker_0): Exactly. They own the only reliable highly detailed map to the entire global mine. And they are charging these pharma companies a literal fortune just to rent access to it. Aaron
- 17:22
- Unidentified speaker (UNKNOWN): Powell And
- 17:22
- Unidentified speaker (speaker_1): the economics of owning that map are brilliant, obviously.
- 17:26
- Unidentified speaker (speaker_0): Right.
- 17:27
- Unidentified speaker (UNKNOWN): But
- 17:27
- Unidentified speaker (speaker_1): we cannot ignore a fundamental vulnerability in how this map is actually maintained. Aaron
- 17:31
- Unidentified speaker (UNKNOWN): Powell
- 17:31
- Unidentified speaker (speaker_0): Oh, the compute costs.
- 17:32
- Unidentified speaker (speaker_1): Yes. Processing this kind of data, specifically spatial biology, whole transcriptum and RNA sequencing. and running these complex agentic AI queries, it requires a staggering computational load.
- 17:45
- Unidentified speaker (UNKNOWN): Aaron Powell
- 17:45
- Unidentified speaker (speaker_0): Let's break down that jargon for a second though. When you say processing spatial biology requires staggering compute, what does that actually mean on a physical level?
- 17:54
- Unidentified speaker (speaker_1): Okay. Think of a tumor not as a solid lump of identical cells, but as is a complex sprawling three 3D D city.
- 18:00
- Unidentified speaker (speaker_0): Okay, a three 3D D city.
- 18:01
- Unidentified speaker (speaker_1): Traditional sequencing. just grinds up the whole city into a smoothie and tells you what building materials are in the cup.
- 18:07
- Unidentified speaker (speaker_0): Just a list of ingredients.
- 18:08
- Unidentified speaker (speaker_1): Exactly. Spatial biology, however, actually maps the city intact.
- 18:14
- Unidentified speaker (speaker_0): Wow.
- 18:14
- Unidentified speaker (UNKNOWN): It
- 18:15
- Unidentified speaker (speaker_1): tells the AI exactly where the cancer cells are hiding, where the immune cells are blocked, and how they interact in three-dimensional space.
- 18:22
- Unidentified speaker (speaker_0): So it's infinitely more complex.
- 18:24
- Unidentified speaker (speaker_1): Yes.
- 18:25
- Unidentified speaker (UNKNOWN): The
- 18:25
- Unidentified speaker (speaker_1): amount of data required to map a single tumor in 3D is exponentially larger than a traditional genetic test. Aaron
- 18:31
- Unidentified speaker (UNKNOWN): Powell And
- 18:32
- Unidentified speaker (speaker_0): Tempest doesn't own the server farms required to crunch those 3D maps, do they?
- 18:36
- Unidentified speaker (speaker_1): Nope, they do not.
- 18:37
- Unidentified speaker (speaker_0): Right.
- 18:38
- Unidentified speaker (UNKNOWN): To
- 18:38
- Unidentified speaker (speaker_1): run this infrastructure, Tempest relies entirely on cloud infrastructure giants like Google Cloud and Amazon Web Services.
- 18:44
- Unidentified speaker (speaker_0): AWS.
- 18:45
- Unidentified speaker (speaker_1): Exactly.
- 18:46
- Unidentified speaker (UNKNOWN): This
- 18:46
- Unidentified speaker (speaker_1): exposes Tempest directly to the pricing power of those tech behemoths.
- 18:51
- Unidentified speaker (speaker_0): Because they're just renting the processing power.
- 18:53
- Unidentified speaker (speaker_1): Exactly. Tempest owns the biological data, but they are renting the computational power to make sense of it. Aaron
- 18:59
- Unidentified speaker (UNKNOWN): Powell And
- 18:59
- Unidentified speaker (speaker_0): if Google or AWS decides to just raise their cloud compute pricing by twenty percent?
- 19:03
- Unidentified speaker (speaker_1): Kempus' gross margins on that AI processing take a direct hit. They have no leverage there.
- 19:09
- Unidentified speaker (speaker_0): Right. And that reliance on renting compute power brings us directly into some of the darker much more controversial realities documented in the source material.
- 19:18
- Unidentified speaker (speaker_1): The forensic flags.
- 19:20
- Unidentified speaker (speaker_0): Yes. Owning the map to the gold mine sounds like a flawless business model, but forensic short sellers, most notably Spruce Point Capital, have released reports flagging that some of the major companies paying these lucrative tolls to Tempest might actually be heavily related to Tempest itself. Aaron
- 19:37
- Unidentified speaker (UNKNOWN): Powell Yeah,
- 19:38
- Unidentified speaker (speaker_1): the circular AI activities. Trevor
- 19:40
- Unidentified speaker (UNKNOWN): Burrus
- 19:40
- Unidentified speaker (speaker_0): Exactly. And if we are doing a true investment analysis, we have to look at the facts surrounding these circular AI activities. Aaron
- 19:48
- Unidentified speaker (UNKNOWN): Powell
- 19:48
- Unidentified speaker (speaker_1): And we will review the facts exactly as they are stated in the filings.
- 19:52
- Unidentified speaker (speaker_0): Right. Let's start with Pathos AI.
- 19:54
- Unidentified speaker (speaker_1): Okay. Pathos is an AI drug development firm. And the key detail here is that it was co-founded by Tempest's Tempus' own CEO.
- 20:02
- Unidentified speaker (speaker_0): Oh.
- 20:02
- Unidentified speaker (speaker_1): Yes. And according to the disclosures, Tempest entered into a $55 million dataset licensing agreement with Pathos.
- 20:11
- Unidentified speaker (speaker_0): So Tempus is licensing data to a company its CEO co-founded.
- 20:16
- Unidentified speaker (speaker_1): Correct. And currently, Pathos accounts for approximately $200 million of dollars Tempest's total contract value or TCV.
- 20:25
- Unidentified speaker (speaker_0): $200 Two hundred million of the backlog. is from Pathos.
- 20:28
- Unidentified speaker (speaker_1): That is what the filings show.
- 20:30
- Unidentified speaker (speaker_0): Okay. Then we have the SoftBank joint venture, which operates under the name SB Tempest.
- 20:36
- Unidentified speaker (speaker_1): Right. And the facts regarding SB Tempest show it is a Japanese joint venture.
- 20:40
- Unidentified speaker (speaker_0): Okay.
- 20:40
- Unidentified speaker (speaker_1): It was capitalized with roughly ninety-five million dollars provided by Tempest.
- 20:44
- Unidentified speaker (speaker_0): Tempest put in ninety-five ninety five million.
- 20:46
- Unidentified speaker (speaker_1): And ninety-five ninety five million provided by SoftBank.
- 20:48
- Unidentified speaker (speaker_0): So equal partners.
- 20:50
- Unidentified speaker (speaker_1): Yes.
- 20:51
- Unidentified speaker (UNKNOWN): But
- 20:51
- Unidentified speaker (speaker_1): following that initial capitalization event, Tempest immediately began recognizing ninety five million dollars in total contract value and revenue flowing back from this specific joint venture.
- 21:01
- Unidentified speaker (speaker_0): Wow. So they put in ninety-five million and immediately booked ninety five million in contract value from it. Aaron
- 21:08
- Unidentified speaker (UNKNOWN): Powell
- 21:08
- Unidentified speaker (speaker_1): That is the factual sequence of events.
- 21:10
- Unidentified speaker (UNKNOWN): Aaron Powell
- 21:11
- Unidentified speaker (speaker_0): And the third major forensic flag involves uh the very cloud compute provider we were just talking about, Google Cloud.
- 21:17
- Unidentified speaker (UNKNOWN): Aaron Powell
- 21:18
- Unidentified speaker (speaker_1): Yes. Tempest executed a debt modification involving a $250 million promissory note held with Google. Aaron
- 21:24
- Unidentified speaker (UNKNOWN): Powell Okay,
- 21:25
- Unidentified speaker (speaker_0): so they owed Google $250 million.
- 21:27
- Unidentified speaker (speaker_1): Yes. And as part of this specific financial arrangement, Tempest was permitted to net a principal reduction of that note directly against their ongoing cloud and software expenses.
- 21:36
- Unidentified speaker (UNKNOWN): Aaron Powell So
- 21:36
- Unidentified speaker (speaker_0): they didn't pay cash for the cloud services they just reduced the debt they owed.
- 21:40
- Unidentified speaker (speaker_1): Exactly. And forensic analysts reviewing this transaction estimate that this non-cash operating benefit artificially inflated Tempest's last 12 months adjusted EBITDA by approximately $25.6 million. Aaron
- 21:53
- Unidentified speaker (UNKNOWN): Powell
- 21:53
- Unidentified speaker (speaker_0): $25 million in EBITDA inflation.
- 21:56
- Unidentified speaker (speaker_1): Yes.
- 21:56
- Unidentified speaker (UNKNOWN): In
- 21:56
- Unidentified speaker (speaker_1): terms of operating metrics, that translates to a $320 basis point margin enhancement on paper.
- 22:02
- Unidentified speaker (UNKNOWN): So
- 22:02
- Unidentified speaker (speaker_0): it makes their margins look significantly better than the cash reality. Aaron
- 22:05
- Unidentified speaker (UNKNOWN): Powell
- 22:06
- Unidentified speaker (speaker_1): It does.
- 22:07
- Unidentified speaker (UNKNOWN): Now,
- 22:07
- Unidentified speaker (speaker_0): separate from the corporate accounting maneuvers, the report also highlights significant congressional trading activity that investors should be aware of.
- 22:14
- Unidentified speaker (speaker_1): Right, the insider tracking.
- 22:15
- Unidentified speaker (speaker_0): Exactly.
- 22:16
- Unidentified speaker (speaker_1): According to the mandatory congressional disclosures, Representative Nancy Pelosi executed highly lucrative options trades on TIPISEQIT. TIPIS Equity.
- 22:24
- Unidentified speaker (speaker_0): Okay, what were the details of that trade? Aaron
- 22:25
- Unidentified speaker (UNKNOWN): Powell
- 22:26
- Unidentified speaker (speaker_1): Specifically she purchased 50 TEM call options with a $20 strike price on January 14th, 2025.
- 22:33
- Unidentified speaker (speaker_0): A $20 strike on January 14th, 2025.
- 22:36
- Unidentified speaker (speaker_1): Yes. And exactly a year later, on January 16th, 2026, she exercised those options to acquire the underlying shares.
- 22:43
- Unidentified speaker (speaker_0): Wow. Capturing massive upside.
- 22:45
- Unidentified speaker (speaker_1): Massive upside as the stock had appreciated and was trading well into the 70s by that point. Aaron
- 22:49
- Unidentified speaker (UNKNOWN): Powell So
- 22:50
- Unidentified speaker (speaker_0): looking at those core. corporate governance structures, I mean I have to ask a very pointed question here.
- 22:54
- Unidentified speaker (speaker_1): Go ahead.
- 22:55
- Unidentified speaker (speaker_0): If a massive chunk of your total contract backlog is coming from your own CEO's side project,
- 23:01
- Unidentified speaker (speaker_1): Athos.
- 23:02
- Unidentified speaker (speaker_0): Yeah. And you are booking $95 million in revenue from a joint venture that you literally just funded with ninety-five million of your own capital.
- 23:09
- Unidentified speaker (speaker_1): SB Tempest. tempus.
- 23:10
- Unidentified speaker (speaker_0): Exactly. How much of this top line revenue growth is actually organic market demand?
- 23:15
- Unidentified speaker (UNKNOWN): I
- 23:15
- Unidentified speaker (speaker_0): mean, it feels a bit like paying your landlord by forgiving a loan you made to them a year ago. Aaron
- 23:20
- Unidentified speaker (UNKNOWN): Powell
- 23:20
- Unidentified speaker (speaker_1): That's an interesting analogy.
- 23:21
- Unidentified speaker (speaker_0): Like no cash actually changes hands today, your checking account looks flush, but your underlying business isn't actually generating new cash from customers.
- 23:28
- Unidentified speaker (speaker_1): It is the single most critical question for any analyst trying to build a discounted cash flow model for this company right now.
- 23:34
- Unidentified speaker (speaker_0): It has to be.
- 23:35
- Unidentified speaker (speaker_1): Because impartially assessing the governance, while no regulatory rules appear to be strictly broken by any of these uh related party agreements or debt swaps.
- 23:43
- Unidentified speaker (speaker_0): Sure, it's all legal.
- 23:44
- Unidentified speaker (speaker_1): They severely obscure the true organic cash generating power of the core business.
- 23:49
- Unidentified speaker (speaker_0): Because it's all circular.
- 23:50
- Unidentified speaker (speaker_1): Right. When top line growth metrics and adjusted EBITDA margins are heavily supported by affiliated capital injections or these complex non non-cash cash compute swaps,
- 24:00
- Unidentified speaker (UNKNOWN): it
- 24:00
- Unidentified speaker (speaker_1): makes it incredibly difficult for a retail investor to assess the actual unsubsidized end market demand for these data licensing products.
- 24:09
- Unidentified speaker (speaker_0): Which means as an investor, you cannot just read the headline revenue beats.
- 24:13
- Unidentified speaker (speaker_1): Absolutely not.
- 24:13
- Unidentified speaker (speaker_0): You have to look at the actual cash flow statements.
- 24:16
- Unidentified speaker (speaker_1): Always.
- 24:16
- Unidentified speaker (speaker_0): But regardless of how Tempest manages its internal accounting, they do not operate in a vacuum. Aaron
- 24:22
- Unidentified speaker (UNKNOWN): Powell
- 24:22
- Unidentified speaker (speaker_1): Right. There's the broader world to contend with.
- 24:24
- Unidentified speaker (speaker_0): Exactly. They are forced to navigate a highly volatile, completely unpredictable macroeconomic battlefield. I mean, we are now in the second year of Trump 2.0, and the regulatory and global trade environments are shifting rapidly around this company's entire supply chain. Aaron
- 24:39
- Unidentified speaker (UNKNOWN): Powell
- 24:39
- Unidentified speaker (speaker_1): The macro shifts are immense.
- 24:41
- Unidentified speaker (UNKNOWN): The
- 24:41
- Unidentified speaker (speaker_1): regulatory shifts under the current administration present a fascinating dual-edged dynamic for Tempest. TEMPAS. Aaron
- 24:46
- Unidentified speaker (UNKNOWN): Powell
- 24:46
- Unidentified speaker (speaker_0): Okay, let's start with the domestic side. Aaron
- 24:48
- Unidentified speaker (UNKNOWN): Powell On
- 24:48
- Unidentified speaker (speaker_1): the domestic front, the administration has pushed heavily to the
- 24:50
- Unidentified speaker (UNKNOWN): same.
- 24:51
- Unidentified speaker (speaker_1): curtail the FDA's regulatory oversight on laboratory developed tests or LDTs. Aaron
- 24:56
- Unidentified speaker (UNKNOWN): Powell
- 24:56
- Unidentified speaker (speaker_0): So less FDA red tape for standard lab tests. Aaron
- 24:58
- Unidentified speaker (UNKNOWN): Ross Powell
- 24:59
- Unidentified speaker (speaker_1): Exactly. And for the broader diagnostic industry, this rollback removes a massive layer of compliance friction and cost. Aaron
- 25:05
- Unidentified speaker (UNKNOWN): Ross
- 25:05
- Unidentified speaker (speaker_1): Powell
- 25:05
- Unidentified speaker (speaker_0): Which is great for the smaller labs. Aaron
- 25:07
- Unidentified speaker (UNKNOWN): Ross Powell
- 25:08
- Unidentified speaker (speaker_1): Right. However, TEMPES Tempest executed a brilliant strategic maneuver to insulate its pricing power regardless of this deregulation.
- 25:16
- Unidentified speaker (speaker_0): What did they do?
- 25:17
- Unidentified speaker (speaker_1): They invested the capital and the time to secure full, formal FDA approval for their flagship XT CDX test.
- 25:25
- Unidentified speaker (speaker_0): Even though they didn't technically have to under the new rules.
- 25:27
- Unidentified speaker (speaker_1): Exactly.
- 25:28
- Unidentified speaker (UNKNOWN): And
- 25:28
- Unidentified speaker (speaker_0): securing that FDA approval completely changes the unit economics of the test, right?
- 25:33
- Unidentified speaker (speaker_1): Radically.
- 25:34
- Unidentified speaker (speaker_0): Can you break down the pricing difference between a standard LDT and a fully FDA approved test?
- 25:38
- Unidentified speaker (speaker_1): Sure. So by securing that official FDA stamp, Tempest transitioned the XTCDX test into the Centers for Medicare and Medicaid Services framework for advanced diagnostic laboratory tests.
- 25:50
- Unidentified speaker (speaker_0): ADLTs.
- 25:51
- Unidentified speaker (speaker_1): Yes. And the difference in reimbursement is staggering.
- 25:55
- Unidentified speaker (speaker_0): How staggering?
- 25:56
- Unidentified speaker (speaker_1): Well, under the standard LDT framework, a comprehensive genomic test might reimburse around 2000.
- 26:02
- Unidentified speaker (UNKNOWN): two
- 26:02
- Unidentified speaker (speaker_1): thousand nine hundred dollars.
- 26:04
- Unidentified speaker (speaker_0): Okay.
- 26:04
- Unidentified speaker (speaker_1): Under the ADLT framework, Temphas can command roughly four thousand five hundred dollars per test.
- 26:10
- Unidentified speaker (speaker_0): Wait, four thousand five hundred dollars?
- 26:12
- Unidentified speaker (speaker_1): Yes.
- 26:13
- Unidentified speaker (speaker_0): And the actual cost of the chemicals and the lab time to run the test didn't change at all, did it?
- 26:17
- Unidentified speaker (speaker_1): Not one cent.
- 26:19
- Unidentified speaker (speaker_0): So that extra one thousand six hundred dollars per test it it just drops straight to the gross margin line. Aaron
- 26:24
- Unidentified speaker (UNKNOWN): Powell
- 26:24
- Unidentified speaker (speaker_1): Precisely. It is a massive structural problem. pricing upgrade that drastically improves the profitability of their physical diagnostics funnel. Aaron
- 26:31
- Unidentified speaker (UNKNOWN): Powell That
- 26:32
- Unidentified speaker (speaker_0): is a master stroke. But the macroeconomic picture under Trump 2.0 isn't just about domestic FDA regulation, right? We also have to look at the realities of global trade. Trevor
- 26:42
- Unidentified speaker (UNKNOWN): Burrus
- 26:42
- Unidentified speaker (speaker_1): Right. The tariff situation. Aaron
- 26:43
- Unidentified speaker (UNKNOWN): Powell
- 26:43
- Unidentified speaker (speaker_0): Because in February 2026, the administration imposed a fifteen 15% percent blanket tariff on global imports under Section 122.
- 26:50
- Unidentified speaker (speaker_1): Yes.
- 26:51
- Unidentified speaker (speaker_1): This is where the microeconomic tailwinds for Tempest become absolutely critical.
- 26:56
- Unidentified speaker (speaker_0): How so?
- 26:56
- Unidentified speaker (speaker_1): When that Section 122 tariff was implemented, pharmaceuticals and pharmaceutical active ingredients were specifically exempted from the 15% levy.
- 27:05
- Unidentified speaker (speaker_0): Which acts as a massive protective shield for the balance sheets of Tempest's biggest clients.
- 27:10
- Unidentified speaker (speaker_1): It does. Because the pharmaceutical giants, the Pfizers and GSKs of the world, aren't suddenly absorbing massive unexpected tariff costs on their core drug imports.
- 27:19
- Unidentified speaker (speaker_0): Right.
- 27:20
- Unidentified speaker (UNKNOWN): So
- 27:20
- Unidentified speaker (speaker_1): their internal RD budgets remain completely intact.
- 27:23
- Unidentified speaker (speaker_0): They still have the cash.
- 27:24
- Unidentified speaker (speaker_1): Exactly. They still have the vast capital liquidity required to afford Tempest's multi-million dollar data licensing subscriptions.
- 27:31
- Unidentified speaker (speaker_0): Because if pharma had been hit with that fifteen 15% percent tariff, the first thing they would cut is exploratory AI data licenses.
- 27:38
- Unidentified speaker (speaker_1): Absolutely. The experimental RD is always the first to go. Aaron
- 27:41
- Unidentified speaker (UNKNOWN): Powell
- 27:41
- Unidentified speaker (speaker_0): So the data licensing revenue is protected.
- 27:43
- Unidentified speaker (speaker_1): For now, yes.
- 27:45
- Unidentified speaker (speaker_0): But there is a massive existential headwind hidden deep in the physical supply chain. Aaron
- 27:50
- Unidentified speaker (UNKNOWN): Powell
- 27:50
- Unidentified speaker (speaker_1): The hardware issue.
- 27:51
- Unidentified speaker (speaker_0): Yes. Tempus' entire business model relies on that physical diagnostic funnel hoovering up data.
- 27:58
- Unidentified speaker (UNKNOWN): But
- 27:58
- Unidentified speaker (speaker_0): to run those tests, they rely heavily on sequencing hardware, flow cells, and category. chemical reagents.
- 28:04
- Unidentified speaker (speaker_1): Right.
- 28:04
- Unidentified speaker (speaker_0): And they are heavily tethered to Illumina for that infrastructure. Trade wars and reciprocal export bans from China directly threaten the availability and the pricing of the raw materials Tempest needs just to keep the lights on in its physical labs. Trevor
- 28:17
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 28:17
- Unidentified speaker (speaker_1): It is a severe vulnerability.
- 28:20
- Unidentified speaker (UNKNOWN): So
- 28:20
- Unidentified speaker (speaker_0): what does this all mean? How do you weigh this incredible $1,600 pricing upgrade on their FDA? FDA-approved tests against the looming threat of a disrupted hardware supply chain?
- 28:31
- Unidentified speaker (speaker_1): If we connect this to the bigger picture, you see a management team that is brilliantly playing the regulatory game they can actually control.
- 28:39
- Unidentified speaker (speaker_0): Right.
- 28:39
- Unidentified speaker (speaker_1): Upgrading to Medicare ADLT pricing is an absolute masterclass in margin optimization. Trevor
- 28:45
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 28:45
- Unidentified speaker (speaker_0): It's genius.
- 28:46
- Unidentified speaker (speaker_1): However,
- 28:48
- Unidentified speaker (UNKNOWN): they
- 28:48
- Unidentified speaker (speaker_1): remain physically tethered to geopolitical training. trade disputes that are entirely outside of their control. Trevor
- 28:53
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 28:53
- Unidentified speaker (speaker_0): They can't negotiate with China.
- 28:54
- Unidentified speaker (speaker_1): No.
- 28:55
- Unidentified speaker (UNKNOWN): And
- 28:55
- Unidentified speaker (speaker_1): no matter how advanced their agentic AI models become,
- 28:59
- Unidentified speaker (UNKNOWN): or
- 28:59
- Unidentified speaker (speaker_1): how many synthetic control arms they design,
- 29:02
- Unidentified speaker (UNKNOWN): if
- 29:02
- Unidentified speaker (speaker_1): they cannot source the basic flow cells and reagents to sequence the physical tumor tissue because of a reciprocal trade embargo.
- 29:09
- Unidentified speaker (speaker_0): Then what?
- 29:11
- Unidentified speaker (speaker_1): The data ingestion funnel instantly dries up.
- 29:13
- Unidentified speaker (UNKNOWN): The whole
- 29:14
- Unidentified speaker (speaker_1): engine's engine stops. Aaron
- 29:15
- Unidentified speaker (UNKNOWN): Powell
- 29:15
- Unidentified speaker (speaker_0): And navigating those macro headwinds while simultaneously funding a 500 petabyte AI infrastructure requires immense amounts of capital.
- 29:23
- Unidentified speaker (speaker_1): Immense amounts.
- 29:24
- Unidentified speaker (speaker_0): Which brings us to the most important question for a retail investor. How is management actually allocating shareholder capital to survive and grow? Aaron
- 29:31
- Unidentified speaker (UNKNOWN): Powell
- 29:31
- Unidentified speaker (speaker_1): That's where we look at the Bruce Greenwald analysis.
- 29:33
- Unidentified speaker (speaker_0): Right. The report uses the Bruce Greenwald method to assess their true capital intensity.
- 29:38
- Unidentified speaker (speaker_1): And based on the results of the Bruce Greenwald analysis applied to Tempest's financials, the maintenance capex is astonishingly low.
- 29:45
- Unidentified speaker (speaker_0): How low?
- 29:46
- Unidentified speaker (speaker_1): Coming in at approximately $16.6 million.
- 29:49
- Unidentified speaker (speaker_1): Relative to over $1.2 billion in consolidated sales. Aaron
- 29:54
- Unidentified speaker (UNKNOWN): Ross Powell
- 29:54
- Unidentified speaker (speaker_0): $6 million in maintenance on a billion in sales?
- 29:57
- Unidentified speaker (speaker_1): Yes. Conversely, the growth capex is massive.
- 30:01
- Unidentified speaker (UNKNOWN): So
- 30:01
- Unidentified speaker (speaker_0): what those Greenwald results tell us is that the physical laboratory core of the business, just running the tests and maintaining the equipment, is actually highly capital light.
- 30:09
- Unidentified speaker (speaker_1): Very much so.
- 30:10
- Unidentified speaker (speaker_0): The true massive drains on the company's capital aren't the microscopes in the labs. No.
- 30:15
- Unidentified speaker (UNKNOWN): The
- 30:15
- Unidentified speaker (speaker_0): capital drains are heavily concentrated in SGNA, the exorbitant cloud computing expenses we discussed earlier, and the intense RD required for continually training their biological AI models.
- 30:26
- Unidentified speaker (speaker_1): That is the financial reality of the business. The software side is what eats the cash. Aaron
- 30:31
- Unidentified speaker (UNKNOWN): Powell
- 30:31
- Unidentified speaker (speaker_0): But how does the management's approach to funding that massive growth capex actually impact the retail investor holding the common stock?
- 30:38
- Unidentified speaker (speaker_1): That is where the report delivers a very harsh reality check in its shareholder alignment assessment.
- 30:44
- Unidentified speaker (speaker_0): Oh boy.
- 30:44
- Unidentified speaker (UNKNOWN): The
- 30:45
- Unidentified speaker (speaker_1): alignment profile of Tempus Tempest AI is classified as deeply common shareholder unfriendly.
- 30:51
- Unidentified speaker (speaker_0): It's
- 30:52
- Unidentified speaker (UNKNOWN): a
- 30:52
- Unidentified speaker (speaker_1): strong word for a financial report.
- 30:53
- Unidentified speaker (speaker_0): It is.
- 31:03
- Unidentified speaker (speaker_1): Yes. A prime example of this is how they manage their balance sheet debt.
- 31:07
- Unidentified speaker (UNKNOWN): Aaron Powell
- 31:08
- Unidentified speaker (speaker_0): Okay, let's hear it.
- 31:09
- Unidentified speaker (speaker_1): Tempus Tempest executed a move to eliminate their high high-interest interest term loans by issuing four $460 hundred and sixty million dollars. million in zero percent convertible notes. Aaron
- 31:16
- Unidentified speaker (UNKNOWN): Powell
- 31:16
- Unidentified speaker (speaker_0): Okay, on the surface, if you just read the headline, that sounds like a genius move.
- 31:20
- Unidentified speaker (speaker_1): Right. It completely neutralizes their cash interest payments, which vastly improves short-term liquidity.
- 31:25
- Unidentified speaker (speaker_0): But
- 31:26
- Unidentified speaker (speaker_1): what they actually did was embed a massive structural dilution overhang into the stock. Aaron
- 31:31
- Unidentified speaker (UNKNOWN): Powell
- 31:31
- Unidentified speaker (speaker_0): Because those notes convert to shares eventually. Aaron
- 31:33
- Unidentified speaker (UNKNOWN): Powell
- 31:33
- Unidentified speaker (speaker_1): Exactly. And on top of those convertible notes, heavy stock-based compensation is routinely used. utilized to pay employees and mass the true operating cash burn.
- 31:42
- Unidentified speaker (speaker_0): So they're paying people in stock instead of cash.
- 31:45
- Unidentified speaker (speaker_1): Yes.
- 31:45
- Unidentified speaker (speaker_0): It's like putting retail investors on a financial treadmill that keeps speeding
- 31:49
- Unidentified speaker (UNKNOWN): up.
- 31:49
- Unidentified speaker (speaker_1): That's exactly what it's like.
- 31:50
- Unidentified speaker (speaker_0): The company itself is sprinting brilliantly. They're growing revenue by twenty to thirty percent year over year.
- 31:55
- Unidentified speaker (speaker_1): Right.
- 31:56
- Unidentified speaker (speaker_0): But because of the massive share dilution, constantly expanding the total float of shares,
- 32:00
- Unidentified speaker (UNKNOWN): the
- 32:01
- Unidentified speaker (speaker_0): retail investors on the treadmill are barely moving forward in terms of actual per share value accretion. Aaron
- 32:06
- Unidentified speaker (UNKNOWN): Powell
- 32:07
- Unidentified speaker (speaker_1): The denominator just keeps getting bigger. Trevor
- 32:09
- Unidentified speaker (UNKNOWN): Burrus
- 32:09
- Unidentified speaker (speaker_0): Yeah. Your slice of the pie is getting smaller almost as fast as the pie is growing.
- 32:14
- Unidentified speaker (speaker_1): It is the defining tension of the entire investment thesis here.
- 32:17
- Unidentified speaker (speaker_0): And it really is.
- 32:18
- Unidentified speaker (speaker_1): Because management's capital alignment philosophy relies entirely on a single, highly aggressive premise.
- 32:24
- Unidentified speaker (UNKNOWN): Aaron Powell
- 32:25
- Unidentified speaker (speaker_0): Which is
- 32:25
- Unidentified speaker (UNKNOWN): that
- 32:26
- Unidentified speaker (speaker_1): the hyper-gressive hypergrowth
- 32:27
- Unidentified speaker (UNKNOWN): in
- 32:27
- Unidentified speaker (speaker_1): the high margin data and applications licensing segment will eventually outrun the expanding share count denominator.
- 32:34
- Unidentified speaker (speaker_0): They just have to grow faster than they dilute.
- 32:36
- Unidentified speaker (speaker_1): Right. But if that top line growth slows down for even a quarter or two before they reach sustained, unadjusted free cash flow generation.
- 32:43
- Unidentified speaker (speaker_0): Then what?
- 32:44
- Unidentified speaker (speaker_1): The mathematical weight of that dilution will crush the equity value.
- 32:49
- Unidentified speaker (speaker_0): Which brings us to the ultimate verdict. It is time to synthesize all these conflicting data points.
- 32:53
- Unidentified speaker (speaker_1): Let's do it.
- 32:54
- Unidentified speaker (speaker_0): We have the incredible Q3 cash flow inflection, the massive 500 petabyte data moat.
- 33:01
- Unidentified speaker (speaker_1): The shadow of the circular AI risks.
- 33:03
- Unidentified speaker (speaker_0): Right. The complex Trump 2.0 macroenvironment, and this severe structural shareholder dilution.
- 33:09
- Unidentified speaker (speaker_1): It's a lot to weigh.
- 33:10
- Unidentified speaker (speaker_0): It is. So let's build a unified investment thesis, starting with a deep dive into the SWAT analysis.
- 33:17
- Unidentified speaker (speaker_1): Okay, looking at their strengths first.
- 33:19
- Unidentified speaker (speaker_0): The S in SWAT.
- 33:20
- Unidentified speaker (speaker_1): Yes.
- 33:21
- Unidentified speaker (UNKNOWN): The
- 33:21
- Unidentified speaker (speaker_1): 500 petabyte multimodal data mode is simply unrivaled in the industry.
- 33:25
- Unidentified speaker (speaker_0): No one else has it.
- 33:27
- Unidentified speaker (speaker_1): It simply cannot be replicated overnight by a competitor. They also have the tremendous ADLT pricing advantage, commanding $4,500 per test.
- 33:36
- Unidentified speaker (speaker_0): That's huge.
- 33:37
- Unidentified speaker (speaker_1): And the successful integration of Ambry Genetics has successfully diversified their revenue streams beyond pure oncology into broader genetic testing. Trevor
- 33:45
- Unidentified speaker (UNKNOWN): Burrus, Jr.
- 33:45
- Unidentified speaker (speaker_0): But the weaknesses are glaring and they are mostly structural, right?
- 33:49
- Unidentified speaker (speaker_1): Yes. The structural dilution overhang from the convertible notes, the heavier reliance on stock-based compensation to mask operating expenses, and the persistent gap on unprofitability profitability are significant anchors on the valuation model. Aaron
- 34:03
- Unidentified speaker (UNKNOWN): Powell
- 34:03
- Unidentified speaker (speaker_0): Moving to Opportunities.
- 34:05
- Unidentified speaker (speaker_1): Well, monetizing the agentic AI capabilities, specifically those synthetic control arms we discussed.
- 34:11
- Unidentified speaker (speaker_0): Right.
- 34:11
- Unidentified speaker (speaker_1): And successfully integrating the Personnalis Next personal MRD test to capture the long-term monitoring market, those offer massive multi-billion dollar avenues for future growth. Aaron
- 34:22
- Unidentified speaker (UNKNOWN): Powell
- 34:23
- Unidentified speaker (speaker_0): But the threats represent existential risks. Aaron
- 34:25
- Unidentified speaker (UNKNOWN): Powell
- 34:25
- Unidentified speaker (speaker_1): They really do. The rapidly escalating cloud compute costs required to run spatial biology models.
- 34:31
- Unidentified speaker (speaker_0): The AWS and Google reliance.
- 34:33
- Unidentified speaker (speaker_1): Exactly. Plus the looming risk of trillion dollar tech giants like Google and NVIDIA deciding to just commoditize healthcare AI themselves.
- 34:41
- Unidentified speaker (speaker_0): If they decide to just build the models directly.
- 34:43
- Unidentified speaker (speaker_1): Right.
- 34:44
- Unidentified speaker (UNKNOWN): And
- 34:44
- Unidentified speaker (speaker_1): of course the supply chain exposure to Illumina amidst global tariffs. Any of those could fundamentally break the Tempest business model.
- 34:51
- Unidentified speaker (UNKNOWN): Aaron Powell So
- 34:51
- Unidentified speaker (speaker_0): how does the broader market actually value this incredibly complex web of technological strengths and structural threats?
- 34:58
- Unidentified speaker (speaker_1): Let's look at the multiples.
- 35:00
- Unidentified speaker (speaker_0): Yeah, let's break down the valuation. Aaron
- 35:01
- Unidentified speaker (UNKNOWN): Powell
- 35:02
- Unidentified speaker (speaker_1): Currently Tempest trades at roughly 9.0 times enterprise value to FY26 estimated sales. Aaron
- 35:08
- Unidentified speaker (UNKNOWN): Powell
- 35:08
- Unidentified speaker (speaker_0): Nine times forward sales.
- 35:09
- Unidentified speaker (speaker_1): Yes.
- 35:10
- Unidentified speaker (UNKNOWN): That
- 35:10
- Unidentified speaker (speaker_1): gives the company an enterprise value of about 14.3 billion dollars.
- 35:15
- Unidentified speaker (speaker_0): Okay.
- 35:16
- Unidentified speaker (speaker_1): Interestingly, despite the massive AI narrative surrounding the stock, this multiple is actually quite cheap compared to direct peers in the genetic testing space.
- 35:24
- Unidentified speaker (speaker_0): Really?
- 35:24
- Unidentified speaker (speaker_1): Yeah. Natera, for example, is trading at a significantly richer multiple of roughly twenty point seven times.
- 35:31
- Unidentified speaker (speaker_0): Wow. So they're trading at less than half the multiple of Natera.
- 35:34
- Unidentified speaker (speaker_1): Right.
- 35:35
- Unidentified speaker (speaker_0): But you cannot just compare top top-line line multiples in a vacuum, especially here. You have to view Tempest's valuation through the lens of traditional SaaS metrics. Trevor
- 35:43
- Unidentified speaker (UNKNOWN): Burrus,
- 35:43
- Unidentified speaker (speaker_1): Because they are increasingly pitching themselves as a software data business. Trevor
- 35:47
- Unidentified speaker (UNKNOWN): Burrus
- 35:47
- Unidentified speaker (speaker_0): Exactly. Which means applying the rule of 40.
- 35:50
- Unidentified speaker (speaker_1): Right. The rule of 40 is the classic benchmark for software companies. Aaron
- 35:54
- Unidentified speaker (UNKNOWN): Powell
- 35:54
- Unidentified speaker (speaker_0): How does the math work on that again?
- 35:56
- Unidentified speaker (speaker_1): The principle is simple. You add the company's revenue growth rate to its free cash flow margin.
- 36:01
- Unidentified speaker (speaker_0): Okay.
- 36:01
- Unidentified speaker (UNKNOWN): If the
- 36:02
- Unidentified speaker (speaker_1): combined number is 40 or higher, it is considered a premium healthy software business that successfully balances growth and profitability.
- 36:10
- Unidentified speaker (speaker_0): And how does Tempest score?
- 36:12
- Unidentified speaker (speaker_1): Tempest currently fails this test. They have roughly a 25% revenue growth rate.
- 36:18
- Unidentified speaker (speaker_0): Okay, that's the growth side.
- 36:20
- Unidentified speaker (speaker_1): But a negative 2% free cash flow margin. Aaron
- 36:22
- Unidentified speaker (UNKNOWN): Powell
- 36:23
- Unidentified speaker (speaker_0): So 25 minus 2.
- 36:25
- Unidentified speaker (UNKNOWN): That
- 36:25
- Unidentified speaker (speaker_1): gives them a combined score of 23.
- 36:27
- Unidentified speaker (speaker_0): Which is well below 40. Aaron
- 36:28
- Unidentified speaker (UNKNOWN): Powell
- 36:29
- Unidentified speaker (speaker_1): Exactly. That failure to hit 40 mathematically justifies the discounted 9.0 times multiple relative to elite software peers. Aaron
- 36:37
- Unidentified speaker (UNKNOWN): Powell
- 36:37
- Unidentified speaker (speaker_0): Okay, but what if you don't look at the company as a single entity? What if you break it apart for uh some of the parts or SOTP valuation? Aaron
- 36:44
- Unidentified speaker (UNKNOWN): Powell
- 36:44
- Unidentified speaker (speaker_1): If you strip the business down and value the high margin data and SAS segment independently at roughly four point $4.7 seven billion.
- 36:51
- Unidentified speaker (speaker_0): Okay.
- 36:52
- Unidentified speaker (speaker_1): That leaves the physical diagnostics business valued at $9.6 billion. Aaron
- 36:58
- Unidentified speaker (UNKNOWN): Ross Powell
- 36:58
- Unidentified speaker (speaker_0): So combining those?
- 37:00
- Unidentified speaker (UNKNOWN): And
- 37:00
- Unidentified speaker (speaker_1): when you synthesize the unified valuation model, factoring in both the relative undervaluation compared to peers like Natera and applying a heavy discount for the severe structural dilution risks we talked about. Aaron
- 37:12
- Unidentified speaker (UNKNOWN): Powell
- 37:12
- Unidentified speaker (speaker_0): What's the target?
- 37:14
- Unidentified speaker (UNKNOWN): The
- 37:14
- Unidentified speaker (speaker_1): data in the role report suggests accumulating the stock on market tips below 7450.
- 37:20
- Unidentified speaker (speaker_0): 7450.
- 37:21
- Unidentified speaker (speaker_1): Yes.
- 37:22
- Unidentified speaker (speaker_0): But how does this entire narrative stand up to traditional hard-nosed value investing? Aaron
- 37:28
- Unidentified speaker (UNKNOWN): Powell
- 37:28
- Unidentified speaker (speaker_1): Oh, that's a completely different framework. Aaron
- 37:30
- Unidentified speaker (UNKNOWN): Powell
- 37:30
- Unidentified speaker (speaker_0): Right. If we run Tempest through Warren Buffett's classic conservative investment criteria, what is the actual result? Aaron
- 37:37
- Unidentified speaker (UNKNOWN): Powell
- 37:38
- Unidentified speaker (speaker_1): It is a decisive
- 37:39
- Unidentified speaker (speaker_1): catastrophic fail.
- 37:41
- Unidentified speaker (speaker_0): Catastrophic fails.
- 37:43
- Unidentified speaker (speaker_1): The business model is far too complex and scientifically opaque for the average investor to easily understand.
- 37:48
- Unidentified speaker (speaker_0): Strike one.
- 37:49
- Unidentified speaker (speaker_1): It has absolutely no consistent operating history of gap earnings.
- 37:52
- Unidentified speaker (speaker_0): Strike two.
- 37:53
- Unidentified speaker (speaker_1): The capital allocation strategy is terrible from a pure value perspective, relying heavily on endless dilution rather than returning capital by via a share buybacks.
- 38:02
- Unidentified speaker (speaker_0): Strike three.
- 38:03
- Unidentified speaker (speaker_1): And the return on equity is deeply persistently negative.
- 38:07
- Unidentified speaker (speaker_0): Wow.
- 38:07
- Unidentified speaker (speaker_1): Out of all the classic Buffett criteria, the only test that Tempest actually passes is possessing a formidable, highly defensible economic moat in its proprietary data.
- 38:17
- Unidentified speaker (UNKNOWN): Aaron Powell
- 38:17
- Unidentified speaker (speaker_0): So if a company completely fails the greatest value investors test, does that make it a definitively bad stock? Or does it just mean this is a stock that requires a completely different playbook to understand?
- 38:29
- Unidentified speaker (speaker_1): This raises a really important question about how we classify assets in the modern AI-driven market.
- 38:34
- Unidentified speaker (speaker_0): Because the old rules don't always apply.
- 38:35
- Unidentified speaker (speaker_1): Exactly. Tempest AI is a speculative, hyper-growth venture asset that happens to be trading on the public markets.
- 38:43
- Unidentified speaker (speaker_0): It's venture capital that you can buy on Robinhood.
- 38:45
- Unidentified speaker (speaker_1): Exactly.
- 38:46
- Unidentified speaker (UNKNOWN): It
- 38:46
- Unidentified speaker (speaker_1): is fundamentally incompatible with traditional cash flow-based flow based value investing. You cannot evaluate it the way you evaluate a railroad or a traditional regional bank.
- 38:55
- Unidentified speaker (speaker_0): Right.
- 38:56
- Unidentified speaker (speaker_1): However, for portfolios that are willing to place a calculated bet on the AI disruption of global pharmacology, and crucially, have the risk tolerance to endure the relentless share dilution and the macro tariff volatility.
- 39:09
- Unidentified speaker (UNKNOWN): Trevor Burrus, Jr.:
- 39:10
- Unidentified speaker (speaker_0): Which takes a strong stomach.
- 39:11
- Unidentified speaker (speaker_1): It does. But if you have that, it is a highly attractive foundational asset for the future of medicine.
- 39:17
- Unidentified speaker (speaker_0): It really is a fascinating contradiction of a company.
- 39:21
- Unidentified speaker (speaker_1): It's an enigma.
- 39:22
- Unidentified speaker (speaker_0): I mean, on one hand, you look at the immediate Q3 results and you have this incredible cash flow inflection where they practically hit break-even.
- 39:30
- Unidentified speaker (speaker_1): Right.
- 39:31
- Unidentified speaker (speaker_0): Driven by an insurmountable five hundred 500 petabyte data moat that Big Pharma desperately needs to design the next generation of drugs. Trevor
- 39:38
- Unidentified speaker (UNKNOWN): Burrus
- 39:38
- Unidentified speaker (speaker_1): The moat is undeniable. Trevor
- 39:39
- Unidentified speaker (UNKNOWN): Burrus
- 39:39
- Unidentified speaker (speaker_0): But on the other hand, you have to navigate the murky shadow of these circular AI partnerships, essentially funding their own revenue.
- 39:45
- Unidentified speaker (speaker_1): The governance issues.
- 39:47
- Unidentified speaker (speaker_0): Yes. The reality of massive structural share dilution continuously eating away at your equity.
- 39:52
- Unidentified speaker (UNKNOWN): The
- 39:53
- Unidentified speaker (speaker_1): treadmill.
- 39:53
- Unidentified speaker (speaker_0): And the incredibly complex reality of managing physical supply chains and diagnostic reimbursement tariffs in the current administration's trade environment. Aaron
- 40:01
- Unidentified speaker (UNKNOWN): Powell
- 40:01
- Unidentified speaker (speaker_1): To successfully hold this stock, it requires an investor to balance profound technological optimism about the future of AI with ruthless, unforgiving financial pragmatism about capital allocation.
- 40:14
- Unidentified speaker (speaker_0): That is the perfect way to summarize it. And as you build your own investment thesis on Tempest, I want to leave you with one final provocative thought to mull over.
- 40:22
- Unidentified speaker (speaker_1): Okay, what is it?
- 40:23
- Unidentified speaker (speaker_0): As Tempest builds the world's most powerful agentic AI. models for healthcare, who actually owns the ultimate value of the biological insights that are inevitably discovered?
- 40:34
- Unidentified speaker (speaker_1): Oh, the IP question.
- 40:36
- Unidentified speaker (speaker_0): Think about it.
- 40:37
- Unidentified speaker (UNKNOWN): If
- 40:37
- Unidentified speaker (speaker_0): Tempest's algorithms discover a groundbreaking, multi-billion dollar cure by combining a pharmaceutical company's proprietary clinical trial data with Tempest's massive genomic library. Aaron
- 40:49
- Unidentified speaker (UNKNOWN): Powell
- 40:49
- Unidentified speaker (speaker_1): Whose cure is it?
- 40:51
- Unidentified speaker (speaker_0): Exactly. How will the intellectual property of the future actually be divided? Who gets the patent?
- 40:57
- Unidentified speaker (speaker_1): That is a billion dollar legal question. Aaron
- 40:59
- Unidentified speaker (UNKNOWN): Powell
- 40:59
- Unidentified speaker (speaker_0): Because the company that successfully controls the IP to the AI generated cures of tomorrow won't just be a highly valued diagnostic lab.
- 41:07
- Unidentified speaker (speaker_1): No.
- 41:07
- Unidentified speaker (speaker_0): They will undoubtedly be the most valuable healthcare company on Earth.
- 41:11
- Unidentified speaker (speaker_1): Something to think about.
- 41:12
- Unidentified speaker (UNKNOWN): Thank
- 41:13
- Unidentified speaker (speaker_0): you for joining us on this deep dive. Keep questioning the data. Always look beneath the surface of the SEC filings, and we will see you next time.